Biotechnology firm ImmunityBio has formally resubmitted its application to the U.S. Food and Drug Administration (FDA) for its lead therapy, ANKTIVA. This move follows an initial regulatory setback ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results